Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | GERN |
---|---|---|
09:32 ET | 34643 | 3.51 |
09:34 ET | 9067 | 3.495 |
09:36 ET | 3896 | 3.485 |
09:38 ET | 5919 | 3.49 |
09:39 ET | 6588 | 3.48 |
09:41 ET | 5602 | 3.5 |
09:43 ET | 17462 | 3.515 |
09:45 ET | 21253 | 3.5233 |
09:48 ET | 28890 | 3.505 |
09:50 ET | 11019 | 3.495 |
09:52 ET | 25832 | 3.485 |
09:54 ET | 16192 | 3.49 |
09:56 ET | 28384 | 3.485 |
09:57 ET | 33123 | 3.485 |
09:59 ET | 29356 | 3.5 |
10:01 ET | 23498 | 3.505 |
10:03 ET | 1502 | 3.505 |
10:06 ET | 15211 | 3.515 |
10:08 ET | 17544 | 3.5119 |
10:10 ET | 27558 | 3.51 |
10:12 ET | 17043 | 3.5101 |
10:14 ET | 3794 | 3.51 |
10:15 ET | 21624 | 3.515 |
10:17 ET | 8244 | 3.5 |
10:19 ET | 10594 | 3.5094 |
10:21 ET | 13584 | 3.49 |
10:24 ET | 3232 | 3.495 |
10:26 ET | 3500 | 3.495 |
10:28 ET | 12941 | 3.495 |
10:30 ET | 20601 | 3.5 |
10:32 ET | 21967 | 3.495 |
10:33 ET | 59257 | 3.485 |
10:35 ET | 3428 | 3.48 |
10:37 ET | 15128 | 3.49 |
10:39 ET | 5848 | 3.49 |
10:42 ET | 2872 | 3.495 |
10:44 ET | 19459 | 3.485 |
10:46 ET | 1804 | 3.49 |
10:48 ET | 49324 | 3.475 |
10:50 ET | 2858 | 3.47 |
10:51 ET | 4789 | 3.47 |
10:53 ET | 47477 | 3.47 |
10:55 ET | 21837 | 3.46 |
10:57 ET | 41449 | 3.465 |
11:00 ET | 39129 | 3.475 |
11:02 ET | 43927 | 3.475 |
11:04 ET | 53245 | 3.48 |
11:06 ET | 12022 | 3.4721 |
11:08 ET | 11550 | 3.48 |
11:09 ET | 3490 | 3.475 |
11:11 ET | 11883 | 3.475 |
11:13 ET | 1900 | 3.472 |
11:15 ET | 1439 | 3.475 |
11:18 ET | 2912 | 3.47 |
11:20 ET | 35814 | 3.46 |
11:22 ET | 2888 | 3.46 |
11:24 ET | 9025 | 3.4699 |
11:26 ET | 105138 | 3.47 |
11:27 ET | 1500 | 3.47 |
11:29 ET | 3388 | 3.475 |
11:31 ET | 4513 | 3.475 |
11:33 ET | 2096 | 3.47 |
11:36 ET | 3736 | 3.47 |
11:38 ET | 1954 | 3.47 |
11:40 ET | 13151 | 3.465 |
11:42 ET | 1113 | 3.465 |
11:44 ET | 9144 | 3.46 |
11:45 ET | 2602 | 3.46 |
11:47 ET | 5434 | 3.46 |
11:49 ET | 8331 | 3.46 |
11:51 ET | 48958 | 3.45 |
11:54 ET | 14183 | 3.455 |
11:56 ET | 14595 | 3.45 |
11:58 ET | 7319 | 3.455 |
12:00 ET | 6231 | 3.455 |
12:02 ET | 10917 | 3.455 |
12:03 ET | 7100 | 3.455 |
12:05 ET | 11048 | 3.455 |
12:07 ET | 2175 | 3.45 |
12:09 ET | 10100 | 3.455 |
12:12 ET | 66423 | 3.445 |
12:14 ET | 3950 | 3.445 |
12:16 ET | 9738 | 3.445 |
12:18 ET | 11400 | 3.44 |
12:20 ET | 1471 | 3.445 |
12:21 ET | 11544 | 3.445 |
12:23 ET | 18949 | 3.445 |
12:25 ET | 147920 | 3.46 |
12:27 ET | 33766 | 3.45 |
12:30 ET | 7601 | 3.455 |
12:32 ET | 4595 | 3.455 |
12:34 ET | 2804 | 3.455 |
12:36 ET | 112043 | 3.47 |
12:38 ET | 58857 | 3.49 |
12:39 ET | 22031 | 3.49 |
12:41 ET | 26314 | 3.505 |
12:43 ET | 54892 | 3.53 |
12:45 ET | 92583 | 3.53 |
12:48 ET | 23951 | 3.535 |
12:50 ET | 11079 | 3.53 |
12:52 ET | 90214 | 3.535 |
12:54 ET | 27576 | 3.535 |
12:56 ET | 53179 | 3.5382 |
12:57 ET | 2394 | 3.53 |
12:59 ET | 21934 | 3.525 |
01:01 ET | 85182 | 3.515 |
01:03 ET | 11002 | 3.505 |
01:06 ET | 11750 | 3.505 |
01:08 ET | 600 | 3.5075 |
01:10 ET | 2015 | 3.505 |
01:12 ET | 9000 | 3.505 |
01:14 ET | 14100 | 3.5 |
01:15 ET | 1950 | 3.505 |
01:17 ET | 5215 | 3.505 |
01:19 ET | 108249 | 3.515 |
01:21 ET | 9100 | 3.515 |
01:24 ET | 39490 | 3.505 |
01:26 ET | 11116 | 3.505 |
01:28 ET | 12678 | 3.505 |
01:30 ET | 300 | 3.51 |
01:32 ET | 13392 | 3.505 |
01:33 ET | 82130 | 3.515 |
01:35 ET | 2617 | 3.51 |
01:37 ET | 400 | 3.515 |
01:39 ET | 1705 | 3.515 |
01:42 ET | 8410 | 3.51 |
01:44 ET | 1497 | 3.515 |
01:46 ET | 2485 | 3.5165 |
01:48 ET | 2286 | 3.51 |
01:50 ET | 32887 | 3.505 |
01:51 ET | 40664 | 3.515 |
01:53 ET | 34402 | 3.505 |
01:55 ET | 13144 | 3.5 |
01:57 ET | 2570 | 3.5 |
02:00 ET | 2524 | 3.5 |
02:02 ET | 26708 | 3.495 |
02:04 ET | 29097 | 3.5 |
02:06 ET | 6719 | 3.5 |
02:08 ET | 1200 | 3.495 |
02:09 ET | 14411 | 3.505 |
02:11 ET | 1300 | 3.5 |
02:13 ET | 1070 | 3.505 |
02:15 ET | 3364 | 3.51 |
02:18 ET | 25406 | 3.515 |
02:20 ET | 200 | 3.515 |
02:22 ET | 40371 | 3.51 |
02:24 ET | 34284 | 3.51 |
02:26 ET | 40137 | 3.5099 |
02:27 ET | 1460 | 3.505 |
02:29 ET | 4070 | 3.505 |
02:31 ET | 1590 | 3.51 |
02:33 ET | 1582 | 3.505 |
02:36 ET | 2780 | 3.505 |
02:38 ET | 61265 | 3.48 |
02:40 ET | 2420 | 3.4867 |
02:42 ET | 3051 | 3.48 |
02:44 ET | 15751 | 3.48 |
02:45 ET | 6700 | 3.485 |
02:47 ET | 84388 | 3.49 |
02:49 ET | 14709 | 3.49 |
02:51 ET | 38193 | 3.49 |
02:54 ET | 2450 | 3.495 |
02:56 ET | 1550 | 3.49 |
02:58 ET | 1682 | 3.495 |
03:00 ET | 50927 | 3.5 |
03:02 ET | 2969 | 3.5 |
03:03 ET | 41977 | 3.495 |
03:05 ET | 1400 | 3.49 |
03:07 ET | 1467 | 3.49 |
03:09 ET | 510 | 3.495 |
03:12 ET | 3092 | 3.495 |
03:14 ET | 1520 | 3.4921 |
03:16 ET | 1810 | 3.495 |
03:18 ET | 1489 | 3.49 |
03:20 ET | 6656 | 3.5 |
03:21 ET | 9510 | 3.5 |
03:23 ET | 10652 | 3.495 |
03:25 ET | 407358 | 3.4888 |
03:27 ET | 5100 | 3.4885 |
03:30 ET | 560 | 3.485 |
03:32 ET | 5443 | 3.485 |
03:34 ET | 8882 | 3.48 |
03:36 ET | 2634 | 3.48 |
03:38 ET | 2200 | 3.485 |
03:39 ET | 60928 | 3.495 |
03:41 ET | 5120 | 3.5 |
03:43 ET | 12075 | 3.5 |
03:45 ET | 10663 | 3.495 |
03:48 ET | 118620 | 3.48 |
03:50 ET | 222071 | 3.49 |
03:52 ET | 831799 | 3.495 |
03:54 ET | 11219 | 3.495 |
03:56 ET | 96976 | 3.485 |
03:57 ET | 74667 | 3.485 |
03:59 ET | 829060 | 3.48 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Geron Corp | 2.1B | -10.0x | --- |
Vera Therapeutics Inc | 2.0B | -18.2x | --- |
CG Oncology Inc | 2.2B | -29.0x | --- |
Rocket Pharmaceuticals Inc | 1.9B | -7.5x | --- |
Fusion Pharmaceuticals Inc | 1.8B | -15.2x | --- |
Inhibrx Inc | 1.8B | -6.4x | --- |
Geron Corporation is a late-stage clinical biopharmaceutical company developing investigational first-in-class telomerase inhibitor, imetelstat, to treat hematologic malignancies. The Company is engaged in the development of therapeutic products for oncology. Its lead indication for imetelstat is in Low or Intermediate-1 risk myelodysplastic syndromes. It is developing imetelstat for the treatment of several myeloid hematologic malignancies, including a Phase 3 clinical trial, named IMpactMF, in relapsed/refractory myelofibrosis (MF) with overall survival as the primary endpoint, that is enrolling patients. It is also conducting a Phase 1 combination therapy clinical trial, named IMproveMF, in first-line Intermediate-1, Intermediate-2 or High-Risk myelofibrosis, or frontline MF, that is enrolling patients and imetelstat is being studied in an investigator-led Phase 2 clinical trial, named IMpress, in Intermediate-2 or High-Risk myelodysplastic syndromes and acute myeloid leukemia.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $2.1B |
---|---|
Revenue (TTM) | $520.0K |
Shares Outstanding | 593.1M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.42 |
EPS | $-0.35 |
Book Value | $0.46 |
P/E Ratio | -10.0x |
Price/Sales (TTM) | 3,969.4 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -40,381.92% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.